gnbac1
mAbexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01699555)
Timeline
Indications
Mechanism of action
- Multiple sclerosis–associated retrovirusImmunity, passive
Multiple sclerosis–associated retrovirus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gnbac1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03574428 | Phase 1 | May 8, 2018 | GeNeuro |
| NCT03179423 | Phase 2 | Jun 14, 2017 | GeNeuro, Southern Star Research Pty Ltd. |
| NCT03239860 | Phase 2 | Jun 6, 2017 | GeNeuro, Servier, Worldwide Clinical Trials |
| NCT02782858 | Phase 2 | Apr 1, 2016 | GeNeuro, Servier, Worldwide Clinical Trials |
| NCT02452996 | Phase 1 | Apr 1, 2015 | GeNeuro, Parexel |
| NCT01639300 | Phase 2 | Jul 1, 2012 | GeNeuro, University of Bern |
| NCT01699555 | Phase 1 | Jul 1, 2011 | Covance, GeNeuro |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeNeuro | For profit | 7 | 7 | 2 | 2011 |
| Servier | For profit | 2 | 0 | 1 | 2016 |
| Worldwide Clinical Trials | For profit | 2 | 0 | 1 | 2016 |
| Covance | For profit | 1 | 0 | 1 | 2011 |
| Parexel | For profit | 1 | 0 | 1 | 2015 |
| Southern Star Research Pty Ltd. | For profit | 1 | 0 | 1 | 2017 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2012 |
7 organizations
Page 1 / 1